264 related articles for article (PubMed ID: 27853909)
21. Clinical characteristics of neuroleptic-induced parkinsonism.
Hassin-Baer S; Sirota P; Korczyn AD; Treves TA; Epstein B; Shabtai H; Martin T; Litvinjuk Y; Giladi N
J Neural Transm (Vienna); 2001; 108(11):1299-308. PubMed ID: 11768628
[TBL] [Abstract][Full Text] [Related]
22. [¹²³I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism.
Tinazzi M; Cipriani A; Matinella A; Cannas A; Solla P; Nicoletti A; Zappia M; Morgante L; Morgante F; Pacchetti C; Sciarretta M; Dallocchio C; Rossi S; Malentacchi M; Ceravolo R; Frosini D; Sestini S; Bovi T; Barbui C
Schizophr Res; 2012 Aug; 139(1-3):40-5. PubMed ID: 22727453
[TBL] [Abstract][Full Text] [Related]
23. Parkinsonian axial signs in schizophrenia.
Morgante F; Barbui C; Tinazzi M;
Parkinsonism Relat Disord; 2017 Mar; 36():89-92. PubMed ID: 28038867
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced parkinsonism in the aged. Recognition and prevention.
Gershanik OS
Drugs Aging; 1994 Aug; 5(2):127-32. PubMed ID: 7981484
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
Hansen TE; Brown WL; Weigel RM; Casey DE
J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
[TBL] [Abstract][Full Text] [Related]
26. Failure of recognition of drug-induced parkinsonism in the elderly.
Esper CD; Factor SA
Mov Disord; 2008 Feb; 23(3):401-4. PubMed ID: 18067180
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced movement disorders.
Jiménez-Jiménez FJ; García-Ruiz PJ; Molina JA
Drug Saf; 1997 Mar; 16(3):180-204. PubMed ID: 9098656
[TBL] [Abstract][Full Text] [Related]
28. Drug-induced Parkinson`s disease. A clinical review.
Bohlega SA; Al-Foghom NB
Neurosciences (Riyadh); 2013 Jul; 18(3):215-21. PubMed ID: 23887211
[TBL] [Abstract][Full Text] [Related]
29. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.
Bondon-Guitton E; Perez-Lloret S; Bagheri H; Brefel C; Rascol O; Montastruc JL
Mov Disord; 2011 Oct; 26(12):2226-31. PubMed ID: 21674626
[TBL] [Abstract][Full Text] [Related]
30. Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease.
Morley JF; Duda JE
J Parkinsons Dis; 2014; 4(2):169-73. PubMed ID: 24284418
[TBL] [Abstract][Full Text] [Related]
31. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced parkinsonism in the elderly.
Stephen PJ; Williamson J
Lancet; 1984 Nov; 2(8411):1082-3. PubMed ID: 6150149
[TBL] [Abstract][Full Text] [Related]
33. [Clinical characteristics of drug induced parkinsonism in psychotic patients].
Giroud-Benítez JL; López-Suárez RM; Méndez-Chávez A; Vistorte-Pupo A; González-Torres R; López-Jaén I; Pradere-Pensado JC; Enriquez Lescano Gort L; Paz-Sendin L
Rev Neurol; 2001 Dec 1-15; 33(11):1095-7. PubMed ID: 11785039
[No Abstract] [Full Text] [Related]
34. Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease.
Jeong S; Cho H; Kim YJ; Ma HI; Jang S
PLoS One; 2021; 16(3):e0247354. PubMed ID: 33647030
[TBL] [Abstract][Full Text] [Related]
35. A longitudinal study of correlations among tardive dyskinesia, drug-induced parkinsonism, and psychosis.
Hansen TE; Weigel RM; Brown WL; Hoffman WF; Casey DE
J Neuropsychiatry Clin Neurosci; 1992; 4(1):29-35. PubMed ID: 1352714
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced parkinsonism in a movement disorders unit: A four-year survey.
Jiménez-Jiménez FJ; Ortí-Pareja M; Ayuso-Peralta L; Gasalla T; Cabrera-Valdivia F; Vaquero A; Tejeiro J; García-Albea E
Parkinsonism Relat Disord; 1996 Jul; 2(3):145-9. PubMed ID: 18591033
[TBL] [Abstract][Full Text] [Related]
37. A study of the early signs of drug induced parkinsonism.
Arblaster LA; Lakie M; Mutch WJ; Semple M
J Neurol Neurosurg Psychiatry; 1993 Mar; 56(3):301-3. PubMed ID: 8096240
[TBL] [Abstract][Full Text] [Related]
38. Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: a pilot study.
Blanchet PJ; Normandeau L; Rompré PH
Schizophr Res; 2012 May; 137(1-3):230-3. PubMed ID: 22309978
[TBL] [Abstract][Full Text] [Related]
39. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis.
Teive HA; Troiano AR; Germiniani FM; Werneck LC
Parkinsonism Relat Disord; 2004 Jun; 10(4):243-5. PubMed ID: 15120099
[TBL] [Abstract][Full Text] [Related]
40. Neuroleptic-induced parkinsonism in older schizophrenics.
Hoffman WF; Labs SM; Casey DE
Biol Psychiatry; 1987 Apr; 22(4):427-39. PubMed ID: 2882787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
